Inozyme Pharma Inc. (INZY): Price and Financial Metrics

Inozyme Pharma Inc. (INZY): $3.97

0.03 (+0.76%)

POWR Rating

Component Grades













Add INZY to Watchlist
Sign Up

Industry: Biotech



in industry

INZY Stock Price Chart Interactive Chart >

Price chart for INZY

INZY Price/Volume Stats

Current price $3.97 52-week high $19.58
Prev. close $3.94 52-week low $3.54
Day low $3.83 Volume 75,900
Day high $4.08 Avg. volume 167,127
50-day MA $4.26 Dividend yield N/A
200-day MA $7.84 Market Cap 159.19M

Inozyme Pharma Inc. (INZY) Company Bio

Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

INZY Latest News Stream

Event/Time News Detail
Loading, please wait...

INZY Latest Social Stream

Loading social stream, please wait...

View Full INZY Social Stream

Latest INZY News From Around the Web

Below are the latest news stories about Inozyme Pharma Inc that investors may wish to consider to help them evaluate INZY as an investment opportunity.

Bargain Shopping? 3 “Strong Buy” Stocks That Are Down Over 50%

Who doesn’t like a bargain? In these days, with price inflation hitting hard, we all want to find the best price on every purchase – and that includes our stock purchases. Bargain-conscious investors can still find those fundamentally solid stocks that are trading low; this is the essence of successful stock investing. To make it easy, we’ve done some of the background research. We’ve located three stocks that are down 50% or more, and confirmed that these are Strong Buy stocks, that have gotten plenty of recent approval from the Street’s stock pros.

Michael Marcus on TipRanks | February 10, 2022

Analysts Are Bullish on These Healthcare Stocks: ObsEva SA (OBSV), Inozyme Pharma (INZY)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSV – Research Report), Inozyme Pharma (INZY – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments. ObsEva SA (OBSV) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $15.00. The company's shares closed last Friday at $1.43, close to its 52-week low of $1.35. According to TipRanks.

Howard Kim on TipRanks | February 7, 2022

Inozyme initiated with a buy at H.C. Wainwright on promise of enzyme replacement therapy

H.C. Wainwright had initiated Inozyme Pharma with a buy based on optimism for its enzyme replacement therapy INZ-701.

Seeking Alpha | February 7, 2022

Inozyme Pharma (NASDAQ:INZY) Coverage Initiated by Analysts at Needham & Company LLC

Needham & Company LLC initiated coverage on shares of Inozyme Pharma (NASDAQ:INZY) in a research report report published on Monday, Analyst Ratings Network reports. The firm issued a buy rating and a $23.00 target price on the stock. Separately, Zacks Investment Research lowered shares of Inozyme Pharma from a buy rating to a hold rating []

Dakota Financial News | December 3, 2021

Nuveen Asset Management LLC Raises Position in Inozyme Pharma, Inc. (NASDAQ:INZY)

Nuveen Asset Management LLC lifted its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 122.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,394 shares of the companys stock after purchasing an additional 26,102 shares during the period. Nuveen []

Dakota Financial News | November 30, 2021

Read More 'INZY' Stories Here

INZY Price Returns

1-mo -4.11%
3-mo -31.43%
6-mo -50.38%
1-year -76.80%
3-year N/A
5-year N/A
YTD -41.79%
2021 -66.96%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0064 seconds.